Exosomes Pipeline Insights 2025: A Comprehensive Analysis by DelveInsight Highlighting Innovative Therapeutics, Key Companies, Clinical Milestones, and Future Market Opportunities

DelveInsight's, "Exosomes Pipeline Insight" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Exosomes pipeline landscape. It covers the Exosomes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Exosomes Pipeline Report to explore emerging therapies, key Exosomes Companies, and future Exosomes treatment landscapes @ Exosomes Pipeline Outlook Report- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Exosomes Pipeline Report
• In July 2025, Rion Inc. announced a study is to evaluate the safety and efficacy of PEP-TISSEEL+ Standard of Care (SOC) compared to SOC only treatment in 40 subjects (20 subjects PEP-TISSEEL + SOC and 20 subjects SOC only), specifically for the treatment of their non-healing DFU.
• DelveInsight's Exosomes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Exosomes treatment.
• The leading Exosomes Companies such as Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24 andothers.
• Promising Exosomes Therapies such as CAP-1002, EXO-CD24, AGLE-102, Progenza, EV-101, andothers.

Discover how the Exosomes treatment paradigm is evolving. Access DelveInsight's in-depth Exosomes Pipeline Analysis for a closer look at promising breakthroughs @ Exosomes Clinical Trials and Studies- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Exosomes Emerging Drugs Profile
• CAP-1002: Capricor Therapeutics
Capricor's (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor's scientific founder, Dr. Eduardo Marbán. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. CAP-1002 contains cardiosphere-derived cells, a type of heart cell progenitor, or precursor cell, that secretes tiny vesicles called exosomes. These exosomes then modulate the activity of the immune system and stimulate cellular regeneration. It is being investigated for its potential to modify the immune system's activity to encourage cellular regeneration.

• EXO-CD24: Nano24
EXO-CD24 (CovenD24), is an investigational drug being developed by Nano24. The company has developed a new anti-inflammatory drug, EXO-CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the NF-kB pathway and the production of cytokines/chemokines. EXO-CD24 discriminates damage-from pathogen-associated molecular patterns (DAMPs and PAMPs) therefore does not interfere with viral clearance. EXO-CD24 was produced and purified from CD24-expressing 293-TRExTM cells. Exosomes displaying murine CD24 (mCD24) were also created.

• AGLE-102: Aegle Therapeutics
AGLE 102 is an allogeneic derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerative healing factors to diseased and damaged tissue. The drug is being developed in the Phase I/II stage of its development for the treatment of Burns and Epidermolysis bullosa dystrophica. The drug is also in the preclinical stage of its development for the Graft vs. Host Disease.

• Progenza: Cambium Bio
Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing.

• EV-101: EV Therapeutics
EV Therapeutics is a pre-clinical stage immuno-oncology biotechnology company devoted to developing first-in-class therapies based on modified tumor extracellular vesicles (mTEVs) to significantly transform cancer therapy and other unmet medical needs that are addressable with its proprietary technology platform. The leading candidate EV101, has demonstrated pre-clinical efficacy across solid tumor and advanced metastatic animal models both as a monotherapy and combination therapy with checkpoint inhibitors.

Get a detailed analysis of the latest innovations in the Exosomes pipeline. Explore DelveInsight's expert-driven report today! @ Exosomes Unmet Needs- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Exosomes Companies
Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24 and others.

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Exosomes Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Exosomes Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Exosomes Pipeline Report
• Coverage- Global
• Exosomes Companies- Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24 and others.
• Exosomes Therapies- CAP-1002, EXO-CD24, AGLE-102, Progenza, EV-101, and others.
• Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Exosomes drug development? Find out in DelveInsight's exclusive Exosomes Pipeline Report-access it now! @ Exosomes Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.